Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
30 06 2020
Historique:
entrez: 2 7 2020
pubmed: 2 7 2020
medline: 10 4 2021
Statut: epublish

Résumé

Antibodies (Abs) specific for CD4-induced envelope (Env) epitopes within constant region 1 and 2 (C1/C2) were induced in the RV144 vaccine trial, where antibody-dependent cellular cytotoxicity (ADCC) correlated with reduced risk of HIV-1 infection. We combined X-ray crystallography and fluorescence resonance energy transfer-fluorescence correlation spectroscopy to describe the molecular basis for epitopes of seven RV144 Abs and compared them to A32 and C11, C1/C2 Abs induced in HIV infection. Our data indicate that most vaccine Abs recognize the 7-stranded β-sandwich of gp120, a unique hybrid epitope bridging A32 and C11 binding sites. Although primarily directed at the 7-stranded β-sandwich, some accommodate the gp120 N terminus in C11-bound 8-stranded conformation and therefore recognize a broader range of CD4-triggered Env conformations. Our data also suggest that Abs of RV144 and RV305, the RV144 follow-up study, although likely initially induced by the ALVAC-HIV prime encoding full-length gp120, matured through boosting with truncated AIDSVAX gp120 variants.

Identifiants

pubmed: 32605979
pii: mBio.00208-20
doi: 10.1128/mBio.00208-20
pmc: PMC7327165
pii:
doi:

Substances chimiques

AIDS Vaccines 0
Epitopes, T-Lymphocyte 0
HIV Antibodies 0
HIV Envelope Protein gp120 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI129769
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI150447
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI120756
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI116274
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI124912
Pays : United States

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2020 Tolbert et al.

Références

Blood. 1997 Aug 1;90(3):1109-14
pubmed: 9242542
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9019-24
pubmed: 23661056
PLoS Pathog. 2019 Dec 3;15(12):e1008121
pubmed: 31794588
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Sci Rep. 2020 Feb 7;10(1):2093
pubmed: 32034163
N Engl J Med. 2009 Dec 3;361(23):2209-20
pubmed: 19843557
Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54
pubmed: 12393927
Structure. 2016 May 3;24(5):697-709
pubmed: 27041594
Structure. 2017 Nov 7;25(11):1719-1731.e4
pubmed: 29056481
J Virol. 2014 Jul;88(14):7715-26
pubmed: 24807721
Blood. 2009 Apr 16;113(16):3716-25
pubmed: 19018092
PLoS Pathog. 2015 Mar 25;11(3):e1004772
pubmed: 25807494
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3
pubmed: 15299374
Science. 2012 May 25;336(6084):1030-3
pubmed: 22628654
J Virol. 1994 Dec;68(12):8350-64
pubmed: 7525988
J Virol. 2014 Nov;88(21):12895-906
pubmed: 25165110
Immunol Rev. 2017 Jan;275(1):271-284
pubmed: 28133809
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3952-7
pubmed: 19225108
J Immunol Methods. 2016 Jun;433:51-8
pubmed: 26969387
AIDS Res Hum Retroviruses. 2017 May;33(5):410-423
pubmed: 28006952
PLoS One. 2020 Jan 30;15(1):e0226803
pubmed: 31999736
J Virol. 2015 Sep;89(17):8840-54
pubmed: 26085162
J Virol. 2014 Feb;88(3):1795-808
pubmed: 24284318
J Virol. 2019 May 1;93(10):
pubmed: 30842326
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
Acta Crystallogr D Biol Crystallogr. 1997 May 1;53(Pt 3):240-55
pubmed: 15299926
J Virol. 2018 Jun 13;92(13):
pubmed: 29669829
AIDS Res Hum Retroviruses. 2017 May;33(5):428-431
pubmed: 27846736
Methods Enzymol. 1997;276:307-26
pubmed: 27754618
Nature. 2014 Oct 23;514(7523):455-61
pubmed: 25296255
Science. 2013 Dec 20;342(6165):1484-90
pubmed: 24179160
Front Immunol. 2019 Apr 02;10:677
pubmed: 31001276
Cell Host Microbe. 2019 Apr 10;25(4):578-587.e5
pubmed: 30974085
J Virol. 1999 Nov;73(11):8966-74
pubmed: 10516002
Virology. 2010 Dec 5;408(1):1-13
pubmed: 20863545
J Virol. 2015 Jan;89(1):545-51
pubmed: 25339767
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1166-71
pubmed: 20080564
J Virol. 2015 Dec 30;90(6):2993-3002
pubmed: 26719277
AIDS. 2007 Feb 19;21(4):517-9
pubmed: 17301571
AIDS. 2018 Nov 13;32(17):2439-2451
pubmed: 30234611
J Virol. 1986 Aug;59(2):284-91
pubmed: 3016298
EBioMedicine. 2016 Oct;12:208-218
pubmed: 27633463
J Virol. 1996 Mar;70(3):1863-72
pubmed: 8627711
J Virol. 2019 Jan 17;93(3):
pubmed: 30429344
J Mol Biol. 2007 Sep 21;372(3):774-97
pubmed: 17681537
Cytometry A. 2011 Aug;79(8):603-12
pubmed: 21735545
Proc Natl Acad Sci U S A. 2015 May 19;112(20):E2687-94
pubmed: 25941367
J Virol. 2015 Dec 04;90(4):2127-34
pubmed: 26637462
J Virol. 2011 Jul;85(14):7029-36
pubmed: 21543485
Nature. 2002 Oct 17;419(6908):743-7
pubmed: 12384704
J Biol Chem. 2001 Mar 2;276(9):6591-604
pubmed: 11096108
Science. 2013 Dec 20;342(6165):1477-83
pubmed: 24179159
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32
pubmed: 15572765
Methods Enzymol. 1997;277:366-96
pubmed: 18488318
J Virol. 2020 Jan 31;94(4):
pubmed: 31776278
Acta Crystallogr D Biol Crystallogr. 2007 Jan;63(Pt 1):32-41
pubmed: 17164524
J Virol. 2014 Mar;88(5):2633-44
pubmed: 24352444
Nat Biotechnol. 2003 Jan;21(1):71-6
pubmed: 12483221
J Virol. 2002 Dec;76(23):12123-34
pubmed: 12414953
Viruses. 2019 Jan 16;11(1):
pubmed: 30654465
J Virol. 2017 May 12;91(11):
pubmed: 28331088
J Virol. 2012 Nov;86(21):11521-32
pubmed: 22896626
Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):E69-78
pubmed: 23237851
J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):403-8
pubmed: 19214118
J Virol Methods. 2014 Nov;208:107-14
pubmed: 25125129

Auteurs

William D Tolbert (WD)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Verna Van (V)

Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Rebekah Sherburn (R)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Marina Tuyishime (M)

Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

Fang Yan (F)

Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Dung N Nguyen (DN)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.

Sherry Stanfield-Oakley (S)

Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.

David Easterhoff (D)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Mattia Bonsignori (M)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

Barton F Haynes (BF)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

M Anthony Moody (MA)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.

Krishanu Ray (K)

Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Guido Ferrari (G)

Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, North Carolina, USA.

George K Lewis (GK)

Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Marzena Pazgier (M)

Infectious Disease Division, Department of Medicine of Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA marzena.pazgier@usuhs.edu.
Division of Vaccine Research of Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH